1. Home
  2. TECX vs VALU Comparison

TECX vs VALU Comparison

Compare TECX & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • VALU
  • Stock Information
  • Founded
  • TECX 2019
  • VALU 1931
  • Country
  • TECX United States
  • VALU United States
  • Employees
  • TECX N/A
  • VALU N/A
  • Industry
  • TECX
  • VALU Investment Managers
  • Sector
  • TECX
  • VALU Finance
  • Exchange
  • TECX Nasdaq
  • VALU Nasdaq
  • Market Cap
  • TECX 334.4M
  • VALU 358.0M
  • IPO Year
  • TECX 2018
  • VALU N/A
  • Fundamental
  • Price
  • TECX $22.88
  • VALU $39.80
  • Analyst Decision
  • TECX Strong Buy
  • VALU
  • Analyst Count
  • TECX 5
  • VALU 0
  • Target Price
  • TECX $79.00
  • VALU N/A
  • AVG Volume (30 Days)
  • TECX 249.4K
  • VALU 2.1K
  • Earning Date
  • TECX 08-13-2025
  • VALU 09-12-2025
  • Dividend Yield
  • TECX N/A
  • VALU 3.25%
  • EPS Growth
  • TECX N/A
  • VALU 17.96
  • EPS
  • TECX N/A
  • VALU 2.28
  • Revenue
  • TECX N/A
  • VALU $35,695,000.00
  • Revenue This Year
  • TECX N/A
  • VALU N/A
  • Revenue Next Year
  • TECX N/A
  • VALU N/A
  • P/E Ratio
  • TECX N/A
  • VALU $17.13
  • Revenue Growth
  • TECX N/A
  • VALU N/A
  • 52 Week Low
  • TECX $13.70
  • VALU $32.94
  • 52 Week High
  • TECX $61.07
  • VALU $57.68
  • Technical
  • Relative Strength Index (RSI)
  • TECX 53.91
  • VALU 57.74
  • Support Level
  • TECX $21.41
  • VALU $38.02
  • Resistance Level
  • TECX $23.87
  • VALU $38.84
  • Average True Range (ATR)
  • TECX 1.57
  • VALU 0.68
  • MACD
  • TECX 0.08
  • VALU 0.18
  • Stochastic Oscillator
  • TECX 54.84
  • VALU 100.00

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

Share on Social Networks: